Physician profile
Robin E Mcbride
NPI 1780810325
$2,377.81
in general payments reported to CMS, 2019-2025
28 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $280 · 2023: $26.63 · 2024: $54.45 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784 · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.82 |
| Education | $314.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $448.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $181.23 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Incyte Corporation | $175.24 | 2025 | Jakafi, Niktimvo |
| Janssen Biotech, INC. | $155.15 | 2021-2025 | Carvykti, Rybrevant |
| Astrazeneca Pharmaceuticals Lp | $151.87 | 2025 | Enhertu, Imfinzi, Lynparza |
| Novartis Pharmaceuticals Corporation | $142.98 | 2025 | |
| Adaptive Biotechnologies Corporation | $137.40 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $124.85 | 2023-2025 | Datroway, Enhertu |
| Astellas Pharma US INC | $116.30 | 2025 | Xtandi |
| Seagen INC. | $95.00 | 2025 | |
| Abbvie INC. | $73.16 | 2024-2025 | |
| Sobi, INC | $69.26 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.31 | 2025 | |
| Glaxosmithkline, LLC. | $57.03 | 2025 | Zejula, Jemperli, Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $44.84 | 2025 | Opdivo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $38.72 | 2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $38.59 | 2025 | |
| Celgene Corporation | $33.59 | 2025 | Reblozyl |
| Exelixis INC. | $33.23 | 2025 | Cabometyx |
| Genentech USA, INC. | $32.06 | 2025 | Polivy |
| Janssen Pharmaceuticals, INC | $24.23 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $24.20 | 2025 | Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $22.22 | 2025 | Glassia |
| Deciphera Pharmaceuticals INC. | $21.16 | 2025 | Qinlock, Romvimza |
| Gilead Sciences, INC. | $20.41 | 2025 | Trodelvy |
| Eisai INC. | $19.87 | 2025 | |
| Adc Therapeutics America, INC. | $18.08 | 2025 | |
| Syndax Pharmaceuticals, INC. | $15.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Mcbride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.